Brief: Knight Therapeutics Reports Fourth Quarter And Year-End 2022 Results

Knight Therapeutics

23/03/2023 11:37

March 23 (Reuters) - Knight Therapeutics Inc  GUD.TO :
    * KNIGHT THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END
2022
RESULTS
    * FOR FISCAL 2023, EXPECTS TO REPORT $280 TO $300 MILLION IN
REVENUE
    * QTRLY LOSS PER SHARE $0.13
    * FY2023 REVENUE VIEW C$302.2 MILLION -- REFINITIV IBES DATA
    * Q4 EARNINGS PER SHARE VIEW C$-0.08 -- REFINITIV IBES DATA
    * SEES FISCAL 2023 ADJUSTED EBITDA, AS PERCENTAGE OF
REVENUES,
BETWEEN 13% TO 15% OF REVENUE

Source text for Eikon:  ID:nGNX6crJMD 
Further company coverage:  GUD.TO 

 ((Reuters.Briefs@thomsonreuters.com;))